蒲参胶囊治疗冠心病（痰瘀交阻证）合并高脂血症患者临床观察

发布时间：2018-03-11 13:50

本文选题：蒲参胶囊　切入点：冠心病　出处：《南京中医药大学》2017年硕士论文　论文类型：学位论文

【摘要】：目的:观察蒲参胶囊(由何首乌、蒲黄、丹参、川芎、赤芍、山楂、泽泻、党参组成)治疗冠心病(痰瘀交阻证)合并高脂血症患者临床作用。方法:将符合纳入标准的冠心病(痰瘀交阻证)合并高脂血症患者105例随机分为治疗组70例、对照组35例,两组患者均予常规抗血小板、扩血管、他汀类药(阿托伐他汀)等冠心病规范治疗,治疗组每日加服蒲参胶囊4粒,3次/日。观察治疗后4周、8周、12周患者心绞痛疗效、中医证候积分、血脂水平变化。结果:两组患者治疗后12周心绞痛疗效的总有效率,治疗组为89%,对照组为71%,两组间比较,差异有统计学意义(P0.05)。两组患者治疗后4周、8周、12周中医证候积分均较治疗前降低,差异有统计学意义(P0.05);两组组间比较,治疗组降低幅度优于对照组(P0.05)。两组患者治疗后4周、8周、12周血总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)水平均较治疗前降低,差异有统计学意义(P0.05),两组间比较,治疗组治疗后4周、8周、12周TG水平及治疗后12周LDL-C水平较对照组降低更明显,差异有统计学意义(P0.05)。结论:在应用西医规范治疗方案的基础上,加服蒲参胶囊,可使冠心病稳定性心绞痛患者心绞痛症状明显减轻,使痰瘀交阻证中医证候积分明显降低;尤其是蒲参胶囊与阿托伐他汀联用,可进一步增加高脂血症患者TC、TG及LDL-C水平下降幅度,其疗效明显优于单用阿托伐他汀的对照组患者。
[Abstract]:Objective: to observe Pushen capsule (Radix Polygoni multiflorum, Radix Polygoni Polygoni, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Radix Paeoniae Rubra, Haw@@. Methods: 105 patients with coronary heart disease (phlegm and blood stasis syndrome) and hyperlipidemia were randomly divided into treatment group (n = 70) and control group (n = 35). The patients in both groups were treated with routine anti-platelet, vasodilator and statins (Atto vastatin). The patients in the treatment group were treated with Pushen capsule 4 times a day for 3 times a day, and the effects of angina pectoris were observed in patients with angina pectoris after 4 weeks, 8 weeks and 12 weeks after treatment. Results: after 12 weeks of treatment, the total effective rate of angina pectoris in the two groups was 89 in the treatment group and 71 in the control group. The scores of TCM syndromes in the two groups were significantly lower than those before treatment at 4 weeks and 8 weeks and 12 weeks after treatment, and the difference was statistically significant (P 0.05). The decrease of serum total cholesterol (TCN), triglyceride triglyceride (TGN) and low density lipoprotein cholesterol (LDL-C) levels in the treatment group were significantly lower than those before treatment (P 0.05), and there was a significant difference between the two groups. The levels of TG and LDL-C in the treatment group were significantly lower than those in the control group at 4 weeks, 8 weeks and 12 weeks after treatment, and the difference was statistically significant (P 0.05). Conclusion: on the basis of the standard treatment plan of western medicine, Pushen capsule was added to the treatment group. The symptoms of angina pectoris in patients with stable angina pectoris of coronary heart disease can be obviously alleviated, and the TCM syndromes integral of phlegm and blood stasis syndrome can be reduced obviously, especially when Pushen capsule is used in combination with Atto vastatin, TCTG and LDL-C levels in hyperlipidemia patients were further increased, and the curative effect was better than that in the control group treated with Atto vastatin alone.
【学位授予单位】：南京中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R259

【相似文献】